RiverVest Venture Partners reposted this
Our pivotal Phase 2 T-RRex trial of WU-CART-007 is officially underway! With previous data showing a composite complete remission rate of 73% and 91% overall response rate, WU-CART-007 has the potential to redefine care for patients with relapsed or refractory T-ALL/LBL. Stay tuned as we continue our work to deliver a transformative off-the-shelf CAR-T therapy. More details here: https://bit.ly/4inhOBk
Looks great
Fantastic news!
Life Science Management Consultant | Biotech and Pharma Executive | Chief Commercial Officer | Oncology, Hematology, Rare Disease | US and Global Marketing and Sales Leadership | Portfolio Strategy | Business Development
2wExciting news indeed!